Last $13.40 USD
Change Today +0.405 / 3.12%
Volume 104.1K
GNMK On Other Exchanges
Symbol
Exchange
NASDAQ GM
Frankfurt
As of 8:10 PM 12/18/14 All times are local (Market data is delayed by at least 15 minutes).

genmark diagnostics inc (GNMK) Snapshot

Open
$13.29
Previous Close
$12.99
Day High
$13.48
Day Low
$12.96
52 Week High
01/16/14 - $14.18
52 Week Low
05/21/14 - $8.48
Market Cap
559.0M
Average Volume 10 Days
172.3K
EPS TTM
$-0.93
Shares Outstanding
41.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for GENMARK DIAGNOSTICS INC (GNMK)

Related News

No related news articles were found.

genmark diagnostics inc (GNMK) Related Businessweek News

No Related Businessweek News Found

genmark diagnostics inc (GNMK) Details

GenMark Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, sells, and supports instruments and molecular tests based on its proprietary eSensor detection technology in the United States. The company’s products include XT-8 system, an automated molecular diagnostic system that enables reference laboratories and hospitals to perform molecular diagnostic tests. It also offers 8 diagnostic tests for use with its XT-8 system that includes Cystic Fibrosis Genotyping Test, which detects a panel of mutations associated with cystic fibrosis; Warfarin Sensitivity test that determines an individual’s ability to metabolize the oral anticoagulant warfarin; Thrombophilia Risk Test, which detects an individual’s increased risk of blood clots; and Respiratory Viral Panel test that simultaneously detects and differentiates 14 clinically relevant viruses from patients with influenza-like illnesses. The company’s diagnostic tests also include Hepatitis C Virus Genotyping test for the detection and typing/subtyping of HCV; 3A4/3A5 Genotyping test designed for the detection and genotyping of the alleles of the CYP450 3A4 gene locus and CYP450 3A5 gene locus; and 2C19 Genotyping test for the detection and genotyping alleles of the cytochrome P450 (CYP450) 2C19 gene locus. In addition, the company is engaged in developing a NexGen system to integrate automated nucleic acid extraction and amplification with its eSensor detection technology to enable technicians to place a patient sample into test cartridge and obtain results without any additional steps. Genmark Diagnostics, Inc. is headquartered in Carlsbad, California.

153 Employees
Last Reported Date: 03/11/14

genmark diagnostics inc (GNMK) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $450.0K
Senior Vice President of North American Comme...
Total Annual Compensation: $226.2K
Senior Vice President of International
Total Annual Compensation: $154.8K
Senior Vice President of Human Resources
Total Annual Compensation: $248.1K
Compensation as of Fiscal Year 2013.

genmark diagnostics inc (GNMK) Key Developments

GenMark Diagnostics, Inc. Presents at Canaccord Genuity 2014 Medical Technologies & Diagnostics Forum, Nov-20-2014 09:30 AM

GenMark Diagnostics, Inc. Presents at Canaccord Genuity 2014 Medical Technologies & Diagnostics Forum, Nov-20-2014 09:30 AM. Venue: The Westin Grand Central, New York, New York, United States. Speakers: Scott Mendel, Chief Financial Officer.

Genmark Diagnostics, Inc. Approves an Amendment and Restatement of the By-Laws

On October 28, 2014, the Board of Directors of GenMark Diagnostics, Inc. approved an amendment and restatement of the By-laws of the company, effective immediately, to include a new Article XIV of the By-laws relating to forum selection in connection with certain litigation matters. The new forum selection provision provides that, unless the company consents in writing to the selection of an alternative forum, the sole and exclusive forum for (i) any derivative action or proceeding brought on behalf of the company, (ii) any action asserting a claim of breach of a fiduciary duty owed by any director, officer or other employee of the company to the company or the company's stockholders, (iii) any action asserting a claim against the company arising pursuant to any provision of the Delaware General Corporation Law or the Certificate of Incorporation or By-laws, or (iv) any action asserting a claim against the Company governed by the internal affairs doctrine shall be a state or federal court located within the state of Delaware, in all cases subject to the court's having personal jurisdiction over the indispensable parties named as defendants. The forum selection provision further provides that any person that purchases or otherwise acquires an interest in stock of the company will be deemed to have notice of and agree to comply with the foregoing provisions.

GenMark Diagnostics, Inc. Announces Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014; Revises Earnings Guidance for the Full Year of 2014: Provides Earnings Guidance for the Fourth Quarter 2014

GenMark Diagnostics, Inc. announced unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, the company reported total revenue of $6,300,000 against $4,637,000 a yea ago. Loss from operations was $10,272,000 against $12,291,000 a year ago. Loss before income taxes was $10,274,000 against $10,794,000 a year ago. Net loss was $9,658,000 against $10,817,000 a year ago. Basic and diluted net loss per share was $0.23 against $0.30 a year ago. Non-GAAP net loss was $9,658,000 against $8,555,000 a year ago. Basic and diluted non-GAAP net loss per share was $0.24 against $0.20 a year ago. For the nine months, the company reported total revenue of $20,768,000 against $20,952,000 a yea ago. Loss from operations was $30,396,000 against $24,609,000 a year ago. Loss before income taxes was $30,242,000 against $22,981,000 a year ago. Net loss was $29,651,000 against $23,011,000 a year ago. Basic and diluted net loss per share was $0.72 against $0.69 a year ago. Non-GAAP net loss was $29,651,000 against $20,189,000 a year ago. Basic and diluted non-GAAP net loss per share was $0.23 against $0.24 a year ago. Net cash used in operating activities was $22,232,000 against $17,500,000 a year ago. Purchases of property and equipment were $3,699,000 against $3,273,000 a year ago. The company also increased its full year 2014 guidance. Total year revenue is now expected to exceed $29.0 million and gross margin is expected to be approximately 54%. The company expects about $8 million in revenue and about $4.5 million in gross profit, which gets to about 55% gross margin rate for the fourth quarter.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GNMK:US $13.40 USD +0.405

GNMK Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Cepheid $53.95 USD +4.16
Luminex Corp $18.37 USD +0.41
Nanosphere Inc $0.38 USD +0.0259
QIAGEN NV €19.22 EUR +0.17
Sequenom Inc $3.64 USD +0.12
View Industry Companies
 

Industry Analysis

GNMK

Industry Average

Valuation GNMK Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 19.8x
Price/Book 6.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 17.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GENMARK DIAGNOSTICS INC, please visit www.genmarkdx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.